Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Key Points

• Benjamin Hohl, CFO of Enliven Therapeutics, sold 3,250 shares of the company's stock for approximately $66,300 on September 29th, reducing his ownership by 12.38%.
• Enliven Therapeutics' stock is currently trading at $19.83 with a market capitalization of $1.17 billion, and analysts expect an average earnings per share of -1.95 for the current year.
• The stock has received favorable ratings from analysts, with five maintaining a Buy rating and a consensus price target of $41.20.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the company's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $20.40, for a total value of $66,300.00. Following the completion of the transaction, the chief financial officer directly owned 23,000 shares in the company, valued at approximately $469,200. The trade was a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, August 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.63, for a total value of $67,047.50.
• On Monday, July 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.46, for a total transaction of $66,495.00.
• On Thursday, July 10th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.66, for a total transaction of $22,660.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded down $0.64 during midday trading on Wednesday, reaching $19.83. 289,888 shares of the stock were exchanged, compared to its average volume of 399,478. The company has a 50 day simple moving average of $19.75 and a 200 day simple moving average of $19.60. The stock has a market capitalization of $1.17 billion, a P/E ratio of -9.92 and a beta of 0.88. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently bought and sold shares of ELVN. Ameriprise Financial Inc. purchased a new position in shares of Enliven Therapeutics in the 4th quarter valued at $789,000. Millennium Management LLC raised its stake in shares of Enliven Therapeutics by 108.6% in the 4th quarter. Millennium Management LLC now owns 50,804 shares of the company's stock valued at $1,143,000 after acquiring an additional 26,449 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Enliven Therapeutics by 67.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after acquiring an additional 17,546 shares during the period. California State Teachers Retirement System raised its stake in shares of Enliven Therapeutics by 10.2% in the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock valued at $471,000 after acquiring an additional 1,940 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Enliven Therapeutics by 15.3% in the 4th quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock valued at $1,821,000 after acquiring an additional 10,746 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analyst Weigh In

ELVN has been the subject of several recent analyst reports. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 price objective for the company. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Finally, Robert W. Baird upped their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.